# Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

> **NCT01165502** · PHASE1 · COMPLETED · sponsor: **CellMed AG, a subsidiary of BTG plc.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CM3.1-AC100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01165502
- **Lead sponsor:** CellMed AG, a subsidiary of BTG plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01165502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01165502, "Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01165502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*